IP Verse

Bristol Myers Squibb patent opposition analysis

CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Latest patents of Bristol Myers Squibb opposed by its competitors

Explore Bristol Myers Squibb's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 21, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3781132
Mar 20, 2024Apixaban Formulations1
EP3818078
Feb 28, 2024Methods Of Producing Recombinant Proteins5
EP3631454
Sep 13, 2023Treatment Of Lag-3 Positive Tumors2
EP3559230
Sep 6, 2023Methods For Increasing The Efficiency Of Homology Directed Repair (Hdr) In The Cellular Genome2
EP3227333
Aug 16, 2023Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of Diseases3
EP3463457
Jun 28, 2023Pd-1 Blockade With Nivolumab In Refractory Hodgkin'S Lymphoma2
EP3464368
Jun 28, 2023Use Of An Anti-Pd-1 Antibody In Combination With An Anti-Cd30 Antibody In Lymphoma Treatment1
EP2508188
May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate5
EP3464373
Oct 27, 2021Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal Cancer6
EP3288980
Mar 10, 2021Treatment Of Pd-L1-Positive Melanoma Using An Anti-Pd-1 Antibody5